Imbalance in expression levels of insulin-like growth factor 2 and H19 transcripts linked to progression of hepatocellular carcinoma

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 4085-4089

  Iizuka, Norio ^a   Oka, Masaaki ^a   Tamesa, Takao ^a   Hamamoto, Yoshihiko ^b   Yamada Okabe, Hisafumi ^c  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

H19; Hepatocellular carcinoma; IGF2; Imprinted gene; Microarray

Indexed keywords

GENE PRODUCT; PROTEIN H19; SOMATOMEDIN B; UNCLASSIFIED DRUG; MESSENGER RNA; RNA H19; UNTRANSLATED RNA;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DNA MICROARRAY; FEMALE; FOLLOW UP; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENOME IMPRINTING; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; BIOSYNTHESIS; COHORT ANALYSIS; GENE EXPRESSION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; RNA, UNTRANSLATED;

EID: 14944373311     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Feinberg AP and Tycko B: The history of cancer epigenetics. Nat Rev Cancer 4: 143-153, 2004.
2. Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA, Bolondi L, Croce CM, Barbanti-Brodano G and Negrini M: Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci USA 97: 5445-5449, 2000.
3. Scelfo RA, Schwienbacher C, Veronese A, Gramantieri L, Bolondi L, Querzoli P, Nenci I, Calin GA, Angioni A, Barbanti-Brodano G and Negrini M: Loss of methylation at chromosome 11p15.5 is common in human adult tumors. Oncogene 21: 2564-2572, 2002.
4. Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346, 2002.
5. Poirier K, Chalas C, Tissier F, Couvert P, Mallet V, Carrie A, Marchio A, Sarli D, Gicquel C, Chaussade S, Beljord C, Chelly J, Kerjean A and Terris B: Loss of parental-specific methylation at the IGF2 locus in human hepatocellular carcinoma. J Pathol 201: 473-479, 2003.
6. Brown KW, Villar AJ, Bickmore W, Clayton-Smith J, Catchpoole D, Maher ER and Reik W: Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway. Hum Mol Genet 5: 2027-2032, 1996
7. Constancia M, Dean W, Lopes S, Moore T, Kelsey G and Reik W: Deletion of a silencer element in Igf2 results in loss of imprinting independent of H19. Nat Genet 26: 203-206, 2000.
8. Hark AT and Tilghman SM: Chromatin conformation of the H19 epigenetic mark. Hum Mol Genet 7: 1979-1985, 1998.
9. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM and Tilghman SM: CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405: 486-489, 2000.
10. Webber A, Ingram RS, Levorse JM and Tilghman SM: Location of enhancers is essential for the imprinting of H19 and Igf2 genes. Nature 391: 711-715, 1998.
11. Li X, Nong Z, Ekstrom C, Larsson E, Nordlinder H, Hofmann WJ, Trautwein C, Odenthal M, Dienes HP, Ekstrom TJ and Schirmacher P: Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 57: 2048-2054, 1997.
12. Lee YI, Lee S, Das GC, Park US, Park SM and Lee YI: Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene 19: 3717-3726, 2000.
13. Nardone G, Romano M, Calabro A, Pedone PV, de Sio I, Persico M, Budillon G, Bruni CB, Riccio A and Zarrilli R: Activation of fetal promoters of insulin-like growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 23: 1304-1312, 1996.
14. Sohda T, Iwata K, Soejima H, Kamimura S, Shijo H and Yun K: In situ detection of insulin-like growth factor II (IGF2) and H19 gene expression in hepatocellular carcinoma. J Hum Genet 43: 49-53, 1998.
15. Takeda S, Kondo M, Kumada T, Koshikawa T, Ueda R, Nishio M, Osada H, Suzuki H, Nagatake M, Washimi O, Takagi K, Takahashi T, Nakao A and Takahashi T: Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. Oncogene 12: 1589-1592, 1996.
16. Vernucci M, Cerrato F, Besnard N, Casola S, Pedone PV, Bruni CB and Riccio A: The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis. Oncogene 19: 6376-6385, 2000.
17. Kim KS and Lee YI: Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma.Cancer Lett 119: 143-148, 1997.
18. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimura S and Hamamoto Y: Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62: 3939-3944, 2002.
19. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, Hamada K, Nakayama H, Ishitsuka H, Miyamoto T, Hirabayashi A, Uchimura S and Hamamoto Y: Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361: 923-929, 2003.
20. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Hashimoto K, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimura S and Hamamoto Y: Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis. Oncogene 22: 3007-3014, 2003.
21. Okada T, lizuka N, Yamada-Okabe H, Mori N, Tamesa T, Takemoto N, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimura S, Hamamoto Y and Oka M: Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma. FEBS Lett 555: 583-590, 2003.
22. Iizuka N, Oka M, Yamada-Okabe H, Hamada K, Nakayama H, Mori N, Tamesa T, Okada T, Takemoto N, Matoba K, Takashima M, Sakamoto K, Tangoku A, Miyamoto T, Uchimura S and Hamamoto Y: Molecular signature in three types of hepatocellular carcinoma with different viral origin by oligonucleotide microarray. Int J Oncol 24: 565-574, 2004.
23. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J and Vingron M: Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365-371, 2001.
24. Iizuka N, Oka M, Hamamoto Y, Mori N, Tamesa T, Okada T, Takemoto N, Matoba K, Takashima M, Sakamoto K, Tangoku A, Miyamoto T, Uchimura S, Nakayama H, Hamada K and Yamada-Okabe H: Altered levels of cytochrome P450 genes in hepatitis B or C virus-infected liver identified by oligonucleotide microarray. Cancer Genom Proteom 1: 53-58, 2004.
25. Parkin DM, Bray FI and Devesa S: Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4-S66, 2001.
26. Tepetes KN, Tsamandas AC, Felekouras ES, Salakou SG and Karavias DD: Conversion of unresectable hepatoma to resectable. Report of a case and review of the literature. Hepatogastroenterology 47: 1105-1109, 2000.
27. Bassanello M, Cillo U, Vitale A, Lumachi F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'Amico F, Senzolo M and D'Amico DF: Multimodal approach and its impact on survival for patients with hepatocellular carcinoma. Anticancer Res 23: 4047-4053, 2003.
28. Hsu HC, Tseng HJ, Lai PL, Lee PH and Peng SY: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 53: 4691-4694, 1993.
29. Iizuka N, Oka M, Noma T, Nakazawa A, Hirose K and Suzuki T: NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res 55: 652-657, 1995.
30. Iizuka N, Mori N, Tamesa T, Tangoku A and Oka M: Telomerase activity and Nm23-H2 protein expression in hepatocellular carcinoma. Anticancer Res 23: 43-47, 2003.
31. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST and Wong J: Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 9: 5339-5345, 2003.
32. Tannapfel A, Anhalt K, Hausermann P, Sommerer F, Benicke M, Uhlmann D, Witzigmann H, Hauss J and Wittekind C: Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol 201: 238-249, 2003.
33. Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H and Hirohashi S: Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 105: 527-532, 2003.
34. Uchida K, Kondo M, Takeda S, Osada H, Takahashi T, Nakao A and Takahashi T: Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma. Mol Carcinog 18: 193-198, 1997.